Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7890597 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RO7890597 | EXPERIMENTAL | Participants will receive a single or multiple doses of RO7890597 alone, or with rabeprazole or itraconazole. |
| Placebo | EXPERIMENTAL | Participants will receive single or multiple doses of matching placebo. |
| Name | Type | Description |
|---|---|---|
| RO7890597 | DRUG | Participants will receive RO7890597 as per the schedule described in the protocol. |
| Placebo | DRUG | Participants will receive matching placebo as per the schedule described in the protocol. |
| Rabeprazole | DRUG | Participants will receive rabeprazole as per the schedule described in the protocol. |
| Itraconazole | DRUG | Participants will receive itraconazole as per the schedule described in the protocol. |
Inclusion Criteria: * Agreement to adhere to the contraception requirements. * Body mass index of 18 to 30 kilograms per square meter (kg/m²). Exclusion Criteria: * Pregnant, breastfeeding, or intending to become pregnant during the study or required contraception period. * Treatment with investi...
RO7890597 is an investigational small molecule drug being developed by Roche Holding AG. It is currently in Phase 1 clinical development and is being studied in healthy adult volunteers. No therapeutic indication has been disclosed for this compound.
RO7890597 is being developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the clinical program evaluating this small molecule compound.
RO7890597 is in Phase 1 clinical development. It has not been approved by the FDA and remains an investigational drug. The program currently has one active trial, which is recruiting participants.
RO7890597 is being evaluated in a single Phase 1 trial, NCT07797478, titled A Study of RO7890597 in Healthy Adult Volunteers. The trial is recruiting in the United States and is designed to enroll 139 participants aged 18 years and older.
The Phase 1 trial NCT07797478 is a randomized, double-blind, controlled study of RO7890597 in healthy adult volunteers. It plans to enroll 139 participants of all sexes, aged 18 years and older, at sites in the United States. The study is currently recruiting.